On one hand, studies have documented downregulated CCL19 expression in patients with colorectal and gastric cancers, with high CCL19 levels effectively inhibiting proliferation and migration of these cancer cells (Xu et al. 2018; Zhou et al. 2020). The gene discussed is CCL19; the disease is cancer.